6/29/23, 11:56 PM STONE Pathway Feedback Search Clinical Topics Home Studies STONE STONE Disease Nephrolithiasis Trial question What is the effect of tamsulosin on passage of symptomatic ureteral stones < 9 mm in diameter? Study design Multi-center Double blinded RCT Population Characteristics of study participants 27.0% female N = 512 73.0% male 512 patients (139 female, 373 male) Inclusion criteria: adult patients with a symptomatic urinary stone in the ureter < 9 mm in diameter, as demonstrated on CT Key exclusion criteria: taking exclusionary medications, prior kidney/ureter surgery, admitted to hospital, stone 9 mm, bladder stone, concurrent UTI Interventions N=267 tamsulosin (0.4 mg tablet daily for 28 days) N=245 placebo (identical capsule daily for 28 days) Primary outcome Rate of urinary stone passage at the end of 28-day treatment period https://web.pathway.md/studies/recQfraKZdjDDi8IK 1/2 6/29/23, 11:56 PM STONE Pathway 49.6 % 49.6 47.3 37.2 % 24.8 % 12.4 % No significant difference 0.0 % Tamsulosin Placebo No significant difference in the rate of urinary stone passage at the end of 28-day treatment period (49.6% vs. 47.3%; RR 1.05, 95% CI 0.87 to 1.27) Secondary outcomes No significant difference in stone passage on follow-up CT (83.6% vs. 77.6%; RR 1.08, 95% CI 0.95 to 1.22) Safety outcomes No significant difference in adverse events. Conclusion In adult patients with a symptomatic urinary stone in the ureter < 9 mm in diameter, as demonstrated on CT, tamsulosin was not superior to placebo with respect to the rate of urinary stone passage at the end of 28-day treatment period. Reference Meltzer AC, Burrows PK, Wolfson AB et al. Effect of Tamsulosin on Passage of Symptomatic Ureteral Stones: A Randomized Clinical Trial. JAMA Intern Med. 2018 Aug 1;178(8):1051-1057. Open reference URL https://web.pathway.md/studies/recQfraKZdjDDi8IK 2/2